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ABSTRACT
Uncoupling protein 1 (UCP1) is a classical feature of brown adipocytes and
understanding its regulatory mechanism will help in the development of a pharmacological
approach for obesity and associated metabolic diseases. The epigenetic regulation of UCP1 in
brown adipocytes is not completely understood. Our study is focused on histone deacetylases
(HDACs), which are set of enzymes that bring about changes in gene expression pattern by
changing the histone acetylation status. Our data suggest that inhibition of Class-I HDACs can
increase the expression of UCP1 in brown and white adipocytes; whereas inhibition of Class-II
HDACs can decrease the UCP1 expression in brown adipocytes. Thus, by pharmacologically
targeting specific HDAC enzymes, it might be possible to modulate UCP1 expression and
thermogenic function in brown and white adipocytes. This will help burning excessive energy in
the form of heat and in turn promote reduction of body weight, alleviate obesity and associated
metabolic diseases.
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INTRODUCTION

Obesity is a medical condition which is characterized by excessive storage and
accumulation of body fat. This accumulation of adiposity causes several additional metabolic
disorders such as: diabetes, hypertension, dyslipidemia, fatty liver (non-alcoholic) syndrome and
cardio-vascular diseases. The co-morbidities associated with obesity pose a severe threat to
human life and quality of living. Thus, a treatment to obesity will not only promote weight loss
but also improve the quality of human life.

Adipose tissue has a fundamental role in both distribution and storage of energy and thus
contributes equally to energy homeostasis and metabolism. Adipose tissue is broadly classified
into two main types: white adipose tissue (WAT), which preserves the energy in the form of triglycerides and brown adipose tissue (BAT), which wastes energy in the form of heat using uncoupling protein 1 (UCP1). This process is called non-shivering thermogenesis and is driven by
uncoupling oxidative phosphorylation in mitochondria1. UCP1 can also be induced in white fat.
Such cells that express UCP1 in WAT are called beige cells2. As energy is dissipated by this
special protein-UCP1 in the form of heat, it is of special interest and target for scientists to study
its mechanisms to treat obesity and promote weight loss. UCP1 expression can be up-regulated
using stimulatory responses such as prolonged cold exposure and stimulation by adrenergic
receptors3. Recent studies have shed insight into the molecular mechanisms behind UCP1
induction in WAT. One such study have stated how positive regulators like peroxisome
proliferator-activated receptor gamma (PPARγ), Peroxisome proliferator-activated receptor
gamma co-activator 1-alpha (PGC1α) and Peroxisome proliferator-activated receptor gamma coactivator 1-beta (PGC1β), PR domain containing 16 (PRDM16), and negative regulators like
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Retinoblastoma (Rb), receptor interacting protein 140 (RIP140) contributes towards
transcriptional regulation of UCP112.

PGC1α and PGC1β are two transcriptional co-activators which are closely related to each
other and they play a vital role in up-regulation of fatty acid oxidation genes. They are also
known to increase mitochondrial biogenesis18. PRDM16 is a classical gene in brown fat fate
determination, which increases the expression of PGC1α, and interacts with important regulators
of brown fat function, including PGC1α, PGC1β, PPARα and PPARγ, thereby promoting brown
adipocyte phenotype and thermogenic function24. Higher levels of PGC1α and PGC1β mRNA
expression are necessary for expression of UCP1 and are inversely correlated with obesity18.
Recent studies also state that the interaction between PPARγ and PGC1α greatly augments the
activity of PPARγ in up-regulation of UCP1 expression. This evidence throws light on the
importance of PGC1α and PGC1β in regulation of brown fat phenotype, as well as UCP1
expression.

On the other hand, it is fairly necessary to understand the repressive mechanisms of
UCP1. The retinoblastoma protein (Rb) belongs to retinoblastoma gene family, is one of the
classical repressors of UCP1 expression. Rb has an ability to switch between the WAT and BAT
fate and is involved in cell cycle and differentiation42. Rb protein phosphorylation or any other
functional inactivation of Rb protein has been correlated with induction of brown fat fate and
higher expression of UCP1 expression in WAT16. These studies demonstrate a repressive role of
Rb1 in UCP1 expression. Interactions between Rb and FOXC2 are postulated to be involved in a
signaling cascade that increases the level of a UCP1 regulatory protein, Protein Kinase A-RIα17.
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Great effort has been devoted to unravel the regulation of brown fat function by these
signaling pathways. The epigenetic regulation and mechanisms of UCP1 expression, however,
are largely unexplored. Through this study, we mainly addressed the questions behind the
epigenetic control mechanisms of UCP1. Understanding these mechanisms will help in
promoting brown fat function and induction of brown fat mechanisms in white adipocytes to
promote weight loss.

Epigenetics is the study of heritable modifications in the patterns of gene expression
caused by mechanisms other than alterations in the actual DNA sequence itself 4. This is either
due to DNA methylation or histone modifications including acetylation, ubiquitination,
methylation, ADP-ribosylation, phosphorylation and sumoylation. Epigenetic control of obesity
has been previously reported in the literature. Recent research has demonstrated that histone 3
lysine 9 [H3-K9] specific demethylase Jhdm2a, plays an important role in obesity by controlling
the expression of PPARα and UCP115. In addition, the pattern of CpG island methylation of the
enhancer regions of UCP1 is found to be specific to the tissues and thus alters the expression
pattern of the UCP1 protein in different tissues6. Furthermore, nuclear hormone co-repressor,
RIP 140 is involved in increasing the assembly of histone methyltransferase on UCP1 enhancer
regions. This specifically methylates the CpG islands of the enhancer regions of UCP1 and its
co-activators, leading to UCP1 suppression7. All of these validate the significance of epigenetics
in the control of adipose tissue metabolism and function. The role of HDAC modulation of
UCP1 gene expression in brown adipocytes, however, remains unidentified.
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HDACs are a set of enzymes, which acts on histones to remove acetyl groups from them.
This modification, enhances the ability of histones to wrap around the DNA more tightly.
Inhibiting HDAC causes up-regulation whereas activating HDAC causes down-regulation of
genes. HDACs are divided into four different super families: Class I to IV. Class I is comprised
of HDAC- 1, 2, 3 and 8, whereas Class II-a includes HDAC-4, 5, 7, and 9, and Class II-b
includes HDAC 6 and 10. Class IV includes HDAC 11. HDAC III includes the sirtuins, which
uses NAD+ as cofactor and hence different from the rest of HDACs 8, 9. In the current project, we
mainly focused on Class I and II HDACs.

Our preliminary data indicate that TSA (pan HDAC inhibitor) down-regulates UCP1
expression. In contrary, a recent study has revealed that injection of Class I HDAC inhibitors in
mice increases mitochondrial activity, ameliorates obesity and insulin resistance in skeletal
muscles and increases UCP1 expression in brown adipose tissue10. On one hand, this provides
confirmation that chromatin modification using pharmacological agents could play an important
role in treatment of obesity. On the other hand, these seemingly contradictory effects of the panHDAC inhibitor TSA and the class I HDAC inhibitor on oxidative pathway and UCP1
expression may be due to the action of different classes of HDACs in the body. The precise
mechanism by which different classes of HDACs regulate UCP1 expression is not clear. Thus,
we studied the contrasting roles of this epigenetic mechanism in UCP1 expression in order to
provide more insight towards formulation of new therapeutics for obesity and diabetes.

Therefore, in this project, we analyzed the roles of different classes of HDACs in the
regulation of brown adipocyte UCP1 expression and function. We hypothesize that there are two
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different regulatory mechanisms in UCP1 expression by HDACs. Inhibiting the Class I HDACs
potentially up-regulated UCP1 expression whereas inhibiting the Class II HDACs downregulated the UCP1 expression. We also studied the mechanisms underlying the differential
regulation of brown adipocyte UCP1 expression and function by the different HDACs.
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2. AIM AND HYPOTHESIS
The overall aim of this study is to identify the mechanisms of epigenetic regulation in
UCP1 expression by histone acetylation.

2.1 Specific aims
1. To evaluate the effect of Class-I HDAC inhibition on UCP1 regulation and brown fat
function
2. To study the role of Class-II HDAC inhibition on UCP1 expression and brown fat
function

2.2 Hypothesis
We hypothesize that there are two different regulatory mechanisms of UCP1 expression
by HDACs. Inhibition of the Class I HDACs can potentially up-regulate UCP1 expression and
on the other hand inhibition of the Class II HDACs can down-regulate the UCP1 expression.

7
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MATERIALS AND METHODS

3.1 Chemical reagents
All HDAC inhibitors, MS-275, MC 1568 and TSA (Trichostatin A) was obtained from
selleckchem.com. The working concentrations of these HDAC inhibitors are: TSA- 500nM, MS275- 5µM, MC-1568- 30µM 10.

3.2 Cell culture
Brown adipocytes cell lines, HIB1B and BAT1 and white adipocyte cell line 3T3-L1
were used. HIB1B cells were grown in high glucose Dulbecco's Modified Eagle’s Medium
(DMEM) along with 10% Fetal Bovine Serum (FBS) and 1% Penicillin Streptomycin (PS)
antibiotics at 37ºC in a humidified atmosphere of 5% CO2. 3T3-L1 cells were grown in high
glucose DMEM along with 10% New Born Calf Serum and 1% PS antibiotics at 37ºC in a
humidified atmosphere of 5% CO2. BAT1 cells were grown in DMEM/F-12 nutrient mixture
along with 10% FBS and 1% PS antibiotics at 37ºC in a humidified atmosphere of 5% CO2.
Undifferentiated HIB1B cells and differentiated HIB1B and BAT1 adipocytes were then pretreated with HDAC inhibitors for 30 minutes followed by norepinephrine (HIB1B) or
isoproterenol (BAT1) stimulation for 4 and 3 hours respectively for induction of UCP1
expression. Differentiated 3T3-L1 cells were treated with MS-275 for various time and then cells
were harvested for RNA expression measurement.
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3.3 Differentiation of pre-adipocyte cell lines
3.3.1 3T3L1 adipocyte differentiation
The 3T3L1 cells were grown until post confluent in DMEM high glucose medium, 10%
calf serum and 1% PS. After post confluence 2-3 days, the differentiation was induced using the
mixture containing: DMEM medium, 10% FBS, 1% PS, insulin (800nM), isobutyl-1methylxanthine (500µM) and dexamathason (1µM) for 2 days. After the differentiation, the cells
were maintained in 800nM insulin medium with DMEM, 10% FBS and 1% PS for another 2- 4
days. After complete differentiation of cells, they were grown in regular medium with DMEM,
10% FBS and 1% PS for additional 4- 8 days.

3.3.2 HIB1B brown adipocyte differentiation
The HIB1B cells were allowed to grow confluent and the differentiation medium
containing DMEM medium, 10% FBS, 1% PS, insulin (800nM), isobutyl-1-methylxanthine
(500µM) and dexamethasone (1µM), indomethacin (100µM), thyroid hormone (T3) (1nM) were
added to induce differentiation of cells for 3 days. Followed by this, the medium were changed to
maintenance medium containing DMEM medium, 10% FBS, 1% PS, insulin (800nM) and T3
(1nM) until 8 days.

3.3.3 BAT1 differentiation
The BAT1 cells were allowed to grow until they are 90% confluent. These cells were
then be induced for differentiation for 48 hours using the differentiation mix containing:
DMEM/F-12 medium, 10% FBS, 1% PS, insulin (20nM), isobutyl-1-methylxanthine (500µM)

9

and dexamethasone (0.5µM), indomethacin (125µM), T3 (1nM). The cells were then switched to
maintenance medium containing DMEM/F-12 medium, 10% FBS, 1% PS, insulin (20nM) and
T3 (1nM). The cells differentiated completely in another 5-6 days.

3.4 RNA Isolation and quantitative RT-PCR
Total RNA were isolated and extracted from cells using Tri-Reagent. The quantification
of messenger RNAs of the gene of interest were done using real time-PCR using TaqMan Onestep RT-PCR master mix (Applied BioSystems, Foster City, CA) and Stratagene Mx300P system
(Stratagene, La Jolla, CA). The concentration of the mRNA used were between 8ng to 50ng and
the mRNA quantitation were normalized by the corresponding cyclophilin mRNA measurement.
TaqMan primer/probes for all genes were bought from Applied Biosystems15. The primer
sequence for all the genes are provided in Table1.

3.5 siRNA Knockdown
For knockdown of gene expression in HIB1B cells using siRNA, Reverse Transfection
procedure were followed. In the first step, RNAi duplex-Lipofectamine™, RNAiMAX
complexes were prepared. For this, 6 pmol RNAi duplex was diluted in 100 µl Opti-MEM® I
Medium containing no serum and gently mixed. 1.5 µl of Lipofectamine™ RNAiMAX were
added and the obtained mix was incubated for 10-20 minutes at RT. Next, the cells which were
allowed to grow to 90% confluence were trypsinized and these cells were diluted in the growth
medium without antibiotics. The concentration of the cells were optimized to 1x 105 cells/well.
This will ensure that 500 µl has the appropriate amount of cells to provide 30-50% confluence
after plating. Then the mixture containing RNAi duplex - Lipofectamine™ RNAiMAX
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complexes and cells were plated. The cells were incubated for 24-72 hours at 37ºC in a CO2
incubator. They were then be pre-treated with HDAC inhibitors for 30 minutes followed by 4
hours of adrenergic stimulation (nor-epinephrine treatment). Then the gene expression was
analyzed.

For siRNA knock down of gene expression in BAT-1 cells, Electroporation technique
were used. The cells obtained from Day 4 differentiation were trypsinized and diluted to the
concentration of 3x106 cells/plate in the medium without antibiotics. Based on manufacture’s
instruction from Lonza (Amaxa Cell Line Nuclefector Kit L) 400µL of Nucleofector solution L
was added. After this, 20pmol of siRNA was added per sample. This mixture will then be
electroporated using Amaxa biosystems. Immediately after electroporation, the mixture was
transferred to a fresh 50 ml tube and mixed with 500µl of maintenance medium/well and plated.
The cells were incubated at 37ºC in a CO2 incubator for additional 2 days. The cells were then
be pre-treated with HDAC inhibitors for 30 minutes followed by 3 hours of adrenergic
stimulation (isoproterenol treatment). Then the gene expression was analyzed.

3.6 Chromatin Immuno-Precipitation assay
At the 6th day of differentiation, the cells were first with HDAC inhibitors for 30 minutes
and followed by adrenergic stimulation. After treatment, the cells were fixed with 1% of
formaldehyde. Protease inhibitors such as: 1 mM phenylmethylsulfonyl fluoride (PMSF) and
1µg/ml pepstatin A are added to ice cold PBS and this was used to wash the fixed cells. The
cells were scrapped and collected in a conical tube. After a brief centrifugation, the pellet was
suspended in SDS lysis buffer containing 1% SDS, 10mM EDTA and 50mM Tris. The cell
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lysate was sonicated to obtain genomic DNA fragment of length 200–1000 bp. These lysate were
then centrifuged, and the supernatant of the sample was collected. Followed by this, the
supernatant was immuno-precipitated with the antibodies against acetyl histone 3 or antibodies
against specific lysine residues on H3. The immuno-complex which underwent immuneprecipitation were washed and reverse cross-linked using NaCl. Followed by this the samples are
digested with protease K. The DNA was isolated using phenol/chloroform extraction method.
The concentration of DNA was measured using Nano drop and subjected to PCR amplification
of the promoter regions of UCP1, Rb1, and PGC1α genes13. All the antibodies were obtained
from Abcam and Millipore. Sybr Green master mix for qRT-PCR was purchased from Applied
BioSystems, Foster City, CA and Stratagene Mx300P system (Stratagene, La Jolla, CA) were
used to measure the gene expression pattern. The primers for PCR were obtained from Integrated
DNA Technologies and the primer sequence are provided in Table 2.
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Table 1: Primer sequence for TaqMan primer and probes
Gene
Sequence
UCP1

FP: CACCTTCCCGCTGGACACT
RP: CCCTAGGACACCTTTATACCTAATGG
Probe: AGCCTGGCCTTCACCTTGGATCTGA

PGC1α

FP: CATTTGATGCACTGACAGATGGA
RP: CCGTCAGGCATGGAGGAA
Probe: CGTGACCACTGACAACGAGGCC

PGC1β

FP: AGGAAGCGGCGGGAAA
RP: CTACAATCTCACCGAACACCTCAA
Probe: AGAGATTTCGAATGTATACCACACGGCCTTCA

COX-1

FP: TTTTCAGGCTTCACCCTAGATGA
RP: GAAGAATGTTATGTTTACTCCTACGAATATG
Probe: CATGAGCAAAAGCCCACTTCGCCA

ACOX-1

FP: AAGAACTCCAGATAATTGGCACCTA or
RP: AGTGGTTTCCAAGCCTCGAA
Probe: CGGAGATGGGCCACGGAACTCAT
or ATGAGTTCCGTGGCCCATCTCCG

Cyclophilin

FP: GGTGGAGAGCACCAAGACAGA
RP: GCCGGAGTCGACAATGATG
Probe: ATCCTTCAGTGGCTTGTCCCGGCT
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Table 2: Primer sequence for ChIP analysis
Gene
Sequence
UCP1 enhancer FP: CTCCTCTACAGCGTCACAGAGG
region

RP: AGTCTGAGGAAAGGGTTGA

UCP1

start FP: CCCACTAGCAGCTCTTTGGA

region

RP: CTGTGGAGCAGCTCAAAGGT

PGC1α Mef2

FP: GCTCGCTGCATTTCTTTCTT
RP: CCCCACAGACTCAAAAACCA

PGC1α CRE

FP: CAAAGCTGGCTTCAGTCACA
RP: AAAAGTAGGCTGGGCTGTCA

Rb1
region

promoter FP: TACTTGGGTTCGAGTCCTCTGCCAG
RP: AGTTGGCCGTGTTCATGCG
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RESULTS

4.1 Role of pan HDAC inhibitors in brown adipose tissue gene regulation
To examine how different HDACs regulate brown fat metabolism and function, we
initially studied the effect of a pan HDAC inhibitor, TSA on H1B1B cell lines. The cells were
pre-treated with TSA for 30 minutes followed by norepinephrine (adrenergic agonist) stimulation
for 4 hours. After the treatment, a significant decrease of UCP1 expression was observed. Genes
which are known to regulate of brown fat function such as: PPARγ, PRDM16 also showed a
significant decrease. We also saw a decrease in RIP140, which is known as a negative regulator
of UCP1 expression12 (Fig: 1A). In contrast, we also observed a robust increase in PGC1α and
PGC1β which are known as transcriptional co-actiavtors of UCP112. Acetyl Co-A oxidase-1
(ACOX-1), which is involved in β-oxidation of fatty acids also showed a significant increase.
Cell death- inducing DFFA- like effector a (CIDEA), which is postulated as a brown fat specific
gene playing an important role in lipolysis and thermogenesis also increased after treatment with
TSA 36 and 37 (Fig: 1B). SAHA, another pan inhibitor of HDACs showed similar effect to that of
TSA and hence the rest of the experiments were continued with TSA as a pan inhibitor (Fig: 2).
Similar results were observed for differentiated H1B1B cells when treated with TSA (Data not
shown)
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Figure 1: Effect of TSA on H1B1B cells.
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Figure 2: Effect of SAHA on H1B1B cells.

4.2 Contrasting effect of Class-I and Class-II HDAC inhibition on UCP1 expression
We next sought to identify how the specific classes of HDACs modulate gene expression
profile in brown fat metabolism. For this, we pre-treated H1B1B cells with Class-I specific
inhibitor, MS-275 and Class-II specific HDAC inhibitor, MC-1568 followed by norepinephrine
stimulation. We observed a strikingly contrast effect on UCP1 expression. While Class-I HDAC
inhibition showed a significant increase of UCP1 expression, opposite to that of the pan-HDAC
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inhibitors, TSA and SAHA, the Class-II HDAC inhibition showed a significant decrease of
UCP1, similar to that of TSA and SAHA (Fig: 3A and 3B). This contrasting effect of different
HDACs suggests that different HDACs may regulate UCP1 gene expression in different ways.

Figure 3: UCP1 expression in H1B1B cells.
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4.3 Effects of Class-I HDAC inhibitor in brown adipocytes
Similar to its effect on UCP1 expression, the treatment of Class-I HDAC inhibitor MS275 in H1B1B cells also promoted the gene expression of transcriptional activators of UCP1
such as: PGC1α, PGC1β and PPARγ. It also increased the expression of ACOX-1 and CIDEA,
which are associated with oxidation of fatty acids and lipolysis respectively (Fig: 4). These
effects are similar to that of TSA in HIB1B cells. These data indicate that these HDAC inhibitors
regulate the gene expression pattern differently.

4.4 Role of HDAC inhibitors in BAT1 cell lines
To confirm the effect of HDAC inhibition on brown adipocytes, a different brown fat cell
line, BAT-1 were used. The studies were repeated by pre-treating the cell lines with HDAC
inhibitors for 30 minutes and followed by isoproterenol (adrenergic stimulation) for 3 hours. As
seen in H1B1B cell lines, BAT1 cells exhibited a similar gene expression profile after treatment
with HDAC inhibitors. In addition to UCP1 down-regulation, TSA also decreased the gene
expression of PPARγ, PRDM16 and classical brown fat markers like deiodenase-2 (DIO2),
elongation of very long chain fatty acids (ELVOL3), potassium channel, subfamily K, member 3
(KCNK3) and otopetrin 1 (OTOP1) (Fig: 5A and 5B). In contrast, TSA in BAT1 cells
significantly up-regulated PGC1α, PGC1β and ACOX-1, similar to TSA’s effect on these gene
expressions in HIB1B cells.
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Figure 4: Effect of MS-275 in H1B1B cells.
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Figure 5: Effect of TSA in BAT-1 cells.
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Similar to H1B1B cell lines, BAT-1 cells also showed a significant decrease of UCP1
expression after Class-II HDAC inhibition and increase of UCP1 after Class-I HDAC inhibition
(Fig: 6A and 6B).

Figure 6: UCP1 expression in BAT1 cells.
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4.5 Increase in brown fat specific genes after Class-I HDAC inhibition
Analogous to H1B1B cell lines, BAT-1 cells treated with Class-I HDAC inhibitor, MS275 showed a similar gene expression profile pattern. In BAT-1 cells, MS-275 increased the
gene expression of PGC1α, COX-1, ACOX-1 and brown fat markers such as: ELVOL3 and
DIO2 (Fig: 7). This suggests that inhibition of Class-I HDACs plays a crucial role in upregulation of brown fat gene expression whereas inhibition of Class-II HDACs significantly
suppresses UCP1 expression in brown adipocytes.

Figure 7: Effect of MS-275 in BAT1 cells.
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To further investigate the effect of Class-I HDAC inhibitor in promotion of brown fat
morphology, we treated white adipocytes at different time periods starting from 30 minutes to 4
days. 3T3-L1 adipocytes, a classical white adipocyte cell line showed an increase in UCP1
expression after treatment with MS-275 (Fig: 8).This clearly demonstrates the up-regulation of
UCP1 expression by Class-I HDAC inhibition.

Figure 8: Effect of MS-275 on UCP1 expression.
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4.6 Class-II HDAC inhibitors target Rb1 to repress UCP1 expression:
H1B1B and BAT-1 cell lines treated with TSA and MC-1568 showed a significant
decrease of UCP1 expression and a robust increase of Rb1 expression. This suggests that TSA
behaved more like a Class-II HDAC inhibitor in down-regulation of UCP1 expression and upregulation of Rb1 expression. In contrast, the Class-I HDAC inhibitor (MS-275) had a very
minor or no significant effect on Rb1 expression (Fig: 9A and 9B). Since Rb1 is a negative
regulator of UCP1 expression, we hypothesize that this robust increase of Rb1 expression by
TSA and MC-1568 likely contributes to the inhibitory effects of TSA and MC-1568 on UCP1
expression.
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Figure 9: Rb1 expression after HDAC inhibitors treatment.
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4.7 Rb1 mediated epigenetic regulation of UCP1 expression by TSA and MC-1568.
TSA inhibits HDACs, which in turn increases the acetylation levels on histone lysine
sites47. We assessed the changes in histone acetylation status of Rb1 promoter region. Using
ChIP analysis, we studied the histone acetylation pattern of H3K27 residues on Rb1 promoter in
BAT-1 cells after treatment with TSA and MC-1568. Treatment with TSA and MC-1568
enriched acetylated H3K27at the promoter region of Rb1, which may in turn, be responsible for
the increased Rb1 expression observed after TSA and MC-1568 treatment. This increased
expression of Rb1 may then inhibit UCP1 expression17. This demonstrates how the treatment
with Class-II HDAC inhibitor suppressed UCP1 expression by recruiting more acetylated histone
groups on repressor genes, such as Rb1 promoter regions and thus promoting its gene expression
(Fig: 10).

In line with ChIP results, to confirm that increase in Rb1 expression is responsible for
suppression of UCP1 expression, we performed siRNA knockdown of Rb1 in brown adipocytes.
After siRNA knockdown, Rb1 expression was decreased by 70% (Fig: 11A). After knockdown
of Rb1, UCP1 expression was significantly increased at both basal level and isoproterenol
treatment level (Fig: 11B). In addition, Rb1 knock down completely reversed the effect of TSA
on inhibiting UCP1 expression when treated with isoproterenol. Rb1 knockdown also reversed
the effect of MC-1568 on inhibiting UCP1 expression both at the basal level and isoproterenol
stimulated condition.
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Figure 10: Effect of HDACs on Rb1 promoter region.
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Figure 11: Effect of Rb1 knockdown in UCP1 expression.
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4.8 Mechanism of Class-I HDAC inhibition
There are evidence from literature that, PGC1α is important in up-regulation of UCP1
expression2, 12, and 25. To explore the mechanism of Class-I HDAC inhibition in the up-regulation
of UCP1 expression, we treated cells with MS-275 and performed ChIP assay to study the
acetylation status of PGC1α transcriptional regions: Mef2 (Myocyte enhancer factor) and CREB
(cAMP response element blinding region) binding sites. The CREB- and Mef2-binding sites are
two important cis-elements on PGC1α promoter that transactivate its expression25, 26, and 27. Our
results indicate a significant recruitment of acetyl groups to both CREB and Mefs sites, with
CREB-binding site showing the most significant increase in acetylation status over Mef binding
region (Fig: 12A). In addition, MS-275 also promoted acetylation of H3 residues on UCP1 start
and enhancer regions with UCP1-start region showing the most significant effect over the UCP1enhancer region40 (Fig: 12B).
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Figure 12: ChIP analysis after MS-275 treatment.
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The role of PGC1α in mediating the effect of MS-275 in UCP1 expression is verified by
siRNA knockdown of PGC1α. The knockdown efficiency was more than 70% and it
significantly reduced UCP1 expression both at basal level and isoproterenol treatment level. It
also significantly prevented the increase in UCP1 expression after treating the cells with the
compound, MS-275. This suggests that (i) PGC1α is very important for regulating UCP1
expression (ii) PGC1α is mediating MS-275 effect on up-regulating UCP1 expression (Fig: 13).

31

Figure 13: Role of PGC1α knockdown in UCP1 expression.
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DISCUSSION

It is long known that sympathetic activation is important for UCP1 expression. For
example: the activation of β3 adrenergic receptor can up-regulate the protein kinase A (PKA)
signaling pathway, which promotes UCP1 gene expression43, 44. In addition, there are important
transcriptional regulators of UCP1 such as: PGC1α, PGC1β, and PRDM16, which are known to
regulate UCP1 expression. Thus, over expression of PGC1α or PRDM16 can also promote
UCP1 expression

45, 46

. There are evidences that support modification in histone acetylation

pattern and other epigenetic modifications like DNA methylation can also up-regulate UCP1
expression

6,7,10.

However, in spite of the large amount of informations available towards the

regulation of brown fat function by these signaling pathways and transcriptional regulators,
specific information on epigenetic regulation of brown fat metabolism remains unclear. A recent
study on Class-I HDACs revealed its role on oxidative metabolism in skeletal muscle10. Other
previous studies on butyrate, which blocks HDAC function have also reported a positive role of
HDAC inhibition in energy expenditure

28, 29 and 30

. These well-established studies provide

evidence that, HDACs play an important role in energy metabolism.

However the detailed mechanisms of how histone acetylation regulate UCP1 expression
is unclear. Through our study, we have addressed this question by providing a direct evidence for
the mechanism of UCP1 regulation after HDAC inhibition. Although literature provides us with
some insight about the role of Class-I HDACs in adipocytes and myocytes10, the exact
mechanism is still unknown. In addition, the effect of Class-II HDAC in the regulation of UCP1
expression is unclear.
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In our study, we used a pan HDAC inhibitor-TSA, Class-I HDAC inhibitor-MS-275 and
Class-II HDAC inhibitor- MC-1568 on various adipocyte cell lines to understand the molecular
basis and epigenetic mechanisms of the regulation of UCP1 expression by different HDACs. Our
efforts were focused on identifying both the activators and repressors of UCP1 induced by
epigenetic modulation by HDACs.

Our results show that TSA, a pan inhibitor of HDACs, and MC-1568, a class II HDAC
inhibitor, significantly down-regulated UCP1 expression, whereas MS-275, a class I HDAC
inhibitor, significantly up-regulated UCP1 expression. In addition, while TSA behaves more like
a class II HDAC inhibitor in inhibiting UCP1 expression, TSA up-regulates PGC1α expression,
similar to that of the class I HDAC inhibitor, MS-275. These data suggest that different HDACs
may exert different effects regulating brown fat gene expression.

Treatment with MS-275 inhibits the Class-I HDACs and our data suggests that it
increases UCP1 expression in brown adipocyte cell lines (Fig: 3 and 6). This increase in UCP1
expression is correlated with increase in its activator: PGC1α (Fig: 4 and 7). To further evaluate
the role of MS-275 in up-regulation of PGC1α, we performed ChIP on PGC1α. Previously
identified transcriptional enhancer regions of PGC1α: Mef and CRE sites were targeted for our
ChIP expereiemnts10, 25, 26 and 27. Our results on inhibition of Class-I HDACs by MS-275 showed
increased acetylation on both the sites and a more significant effect was seen at the CRE site
(Fig: 12A).

This enrichment of histone acetylation at PGC1α transcription region, after

treatment with MS-275 is consistent with the previous work done by Galmozzi et al10.
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In our study, we have also shown that MS-275 can directly promote acetylation at the
UCP1 transcriptional regulatory and start region. From previous established data, we know that
UCP1 transcriptional regulatory region is present around 2.8 kb from its start site38 and 39. This
region includes binding motifs like: CRE, PPRE (peroxisomal proliferator activator receptor
binding motif), BRE (brown adipocyte regulatory element) and also some negative regulatory
elements, such as Rip-140 binding site. Our results indicate that MS-275 can enrich histone
acetylation at this UCP1 enhancer region, as well as at the UCP1 transcriptional start region (Fig:
12B). We believe, MS-275 can directly act on UCP1 and as well act on UCP1 positive regulator,
PGC1α to up-regulate its expression. Apart from this, MS-275 also increased a whole panel of
brown fat specific genes and thus promoting brown adipocyte function (Fig: 4 and 7). Not only
in brown adipocyte cell line, but also in white adipocyte cell line, MS-275 significantly upregulated UCP1 expression (Fig: 8), indicating that MS-275, by inhibiting Class-I HDACs, may
also be important in the browning of white adipocytes. This compound, MS-275 in animal model
showed a physiological significance in ameliorating obesity and promoted up-regulation of
PGC1α in skeletal muscles in other studies 10. Based on all of these evidences and our results, we
interpret that inhibition of Class-I HDACs play a vital role in enhancing brown adipocyte
function, and in browning of white adipocytes and thus induction of beige cell phenotype in
white adipocytes.

To confirm that treatment with MS-275, exerted its effect on UCP1 by directly targeting
PGC1α, we performed knockdown of PGC1α in brown adipocytes.. After knockdown, we
observed that effect of MS-275 on UCP1 up-regulation was significantly reversed. Thus, the
inhibition of Class-I HDACs increased the acetylation status of PGC1α and as well as increased

35

the acetylation status of both UCP1 start and enhancer region. Taken together, these epigenetic
changes significantly up-regulate UCP1 expression.

On the other hand, both TSA and Class-II HDAC inhibitor, MC-1568 significantly downregulated UCP1 expression. We hypothesize, the inhibition of HDACs by TSA and MC-1568
activate certain repressor genes that are responsible for the suppression of UCP1 expression.
From literature, we know that Rb1 and RIP140 are well documented negative regulators of
UCP1

11, 12, 17 and 18

. Our results indicate that all the HDAC inhibitors used in our study: TSA,

MS-275 and MC-1568 up-regulated RIP140. Whereas only MC-1568 and TSA up-regulated
Rb1,while MS-275 had no effect on Rb1 expression (Fig: 9). Based on this result, we expect
Rb1 to be a likely target for Class-II HDAC inhibitors to down-regulate UCP1 expression.
Therefore, we focused the rest of our experiments on Rb1.

Rb1, which is primarily known as a tumor suppressor gene, is also known to regulate
apoptosis, cell proliferation and differentiation

31-33

. In rodents, Rb1 is known as a negative

regulator of brown adipocyte differentiation34. The inactivation of Rb1 is thought to induce
brown fat like features in white adipocytes. In literature, however there is no clear evidence how
Rb1 gene expression can be regulated by epigenetic mechanisms, which in turn controls UCP1
expression.

Our ChIP results clearly demonstrated that inhibiting Class-II HDACs recruited more
acetyl groups on Rb1 promoter region which may in turn up-regulate its expression (Fig: 10).
This indicates that inhibition of Class-II HDACs promoted Rb1 gene expression and Rb1 being a
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negative regulator of UCP1, can suppresses UCP1 expression by negatively regulating PKACREB pathway17.

The increase in Rb1 expression can indirectly inhibit up-regulation of UCP1 expression
by inhibiting the PKA signaling cascade. PKA signaling cascade can be activated by sympathetic
stimulation. When adrenergic agonists, such as norepinephrine and isoproterenol bind to their GProtein Coupled Receptor (Gs), the Gα subunit is released to activate adenylate cyclase (AC). AC
can catalyze the generation of cAMP, which binds to PKA to release the regulatory subunit from
the catalytic site. The free, activated PKA catalytic unit can now diffuse inside the nucleus to
phosphorylate and activate cAMP Response Element Binding Protein (CREB). The activated
CREB can act on its downstream target or the promoter regions of various genes to up-regulate
their expression. For example, CREB binds directly to UCP1 promoter to activate its gene
expression38 and 39.

From literature, we know that transcription of Protein Kinase A can be differentially
regulated by either up-regulating the synthesis of regulatory subunits or its catalytic subunit35.
Cell utilizes this function to regulate the PKA signaling cascade. Rb1 increases FOXC2
(Forkhead box protein C2), which is a transcription factor belonging to FOX (Forkhead box)
family. This FOXC2 can then increase PKA-RIα (Protein Kinase A- Regulatory Subunit-Iα)
expression, which is a negative regulator of PKA signaling cascade. Thus up-regulation of Rb1
expression via enriched histone acetylation on its promoter can in turn increase the PKA-RIα
subunit. This can suppress UCP1 expression by inhibiting the PKA signaling pathway (Fig 14).
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This is indeed consistent with literature that up-regulation of Rb1 increases PKA-RIα, which
inhibits the upstream signaling of β-agonist to decrease PKA activity17.

38

Figure 14: A cartoon depicting the mechanism of different mode of action by different HDAC inhibitors.
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The following evidences support our hypothesis that Rb1 mediates the effect of Class-II
HDAC inhibitors in suppression of UCP1 expression: i) significant increase in Rb1 expression
after TSA and MC-1568 treatment, which is consistent with significant decrease in UCP1
expression ii) enrichment of H3K27 acetylation at Rb1 promoter region to up-regulate its
expression iii) the ability of Rb1 knockdown to reverse the effect of TSA and MC-1568 in
suppression of UCP1. In summary, all these data clearly demonstrates that Rb1 mediates
suppression of UCP1 expression by TSA and MC-1568 in brown adipocytes. To our knowledge,
this is the first study which links the epigenetic modulation of Rb1 in regulation of UCP1
expression.

In conclusion, we believe that there exists two different regulatory mechanism of UCP1
expression. Class-I HDAC inhibition can up-regulate UCP1 expression through PGC1α and
Class-II HDAC inhibition can down-regulate UCP1 expression through Rb1. To the best of our
knowledge this is the first study which links the epigenetic regulation of UCP1 via HDAC
inhibition.

In spite of understanding the mechanism of Class-I and Class-II HDACs on UCP1
expression, the role of specific HDACs in regulation of UCP1 is yet to be studied. This will
further help us understand how epigenetics control brown fat thermogenesis and what role it
plays in energy balance. By targeting the specific HDACs using synthetic or natural drugs, it
might be possible to develop a promising therapy towards treatment of obesity and its associated
disorders.
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